Streetwise Biotechnology / Pharmaceuticals Articles


Biotech's Target Price Increased as Shares 'Deeply Undervalued'

Research Report
  ()
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer. read more >

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing

Contributed Opinion
  ()
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer. read more >

Biotech with Solid Pipeline and 'Solid Partnership Outlook'

Research Report
  ()
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans. read more >

Analyst Says Biotech Share Price Could Potentially 'Double'

Research Report
  ()
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. read more >

Target Price Raised on 'Undervalued' Antibiotics Developer

Research Report
  ()
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. read more >

Drug Offers 'Best-in-Class' Potential

Contributed Opinion
  ()
John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health. read more >

Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease

Research Report
  ()
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. read more >

Biopharmaceutical Firm Receives FDA Priority Review and PDUFA Date

Research Report
  ()
Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics. read more >

Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'

Research Report
  ()
Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. read more >

Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference

Research Report
  ()
Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting. read more >

Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials

  ()
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia. read more >

Gold at Year-End and a Lesson in Shorting

Contributed Opinion
  ()
Ron Struthers of Struthers' Resource Stock Report provides his outlook on gold stock performance going into the end of the year, offers a lesson in Shorting 101, and discusses his views on particular companies. read more >

Cannabis Company Forms Partnership to Develop Pharmaceuticals

Research Report
  ()
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. read more >

Japan Is Fertile Ground for Biotech Deals

  ()
Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. read more >

Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia

  ()
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts. read more >
Management Q&A: View from the Top

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

Managment Q&A: View from the Top
  ()
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi. read more >

Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'

Research Report
  ()
H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer. read more >

Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential

Research Report
  ()
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. read more >

Gout, Kidney Stones, Liver Disease & Cannabinoids

Contributed Opinion
  ()
Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. read more >

Biopharma Gets Green Light for Hypertension Study

Research Report
  ()
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts. read more >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy

Research Report
  ()
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components. read more >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena

Research Report
  ()
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella. read more >

Medical Cannabis Innovator Set to Go Public

Initial Public Offering
  ()
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. read more >

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection

Research Report
  ()
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations. read more >

Maxim Raises Target Price of Biotech Company

Research Report
  ()
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech. read more >
Showing Results: 26 to 50 of 169 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

More Experts